RedChip Companies

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S. #finance #capitalmarkets #investorrelations

📢 Greenwich LifeSciences (Nasdaq: GLSI): Investor Webinar Set to Spotlight FLAMINGO-01 Phase III Progress Greenwich LifeSciences, Inc. will host a key Investor Webinar next Tuesday at 4:15PM EST, offering an in-depth global update on its Phase III clinical trial, FLAMINGO-01. 💡 Why This Matters to Investors: 🔬 Advancing Toward Commercialization: Early data from both HLA-A02 and non-HLA-A02 patient groups show promising immune response trends, expanding the trial’s potential pathways to approval. 🌍 Global Expansion: With over 117 active sites across the U.S. and EU—and plans to exceed 150—the trial is now one of the most extensive breast cancer studies globally. 🏥 Prestigious Partners: Participation from leading academic hospitals like Stanford University School of Medicine, Harvard Medical School, and Johns Hopkins Medicine, and European networks such as GEICAM, GBG, and Unicancer, adds validation and visibility. 📊 Next Phase of Growth: The webinar will cover clinical updates, regulatory strategy, and commercialization plans, including manufacturing and patent outlooks for GLSI-100. 🔗 https://lnkd.in/efUguQhq Breast Cancer Trials Biotechnology Biotechnology News #RedChip #RedChat #GreenwichLS #BreastCancer #InsiderOwnership #BiotechNews #Oncology #FinancialNews #CapitalMarkets

📢 Institutional Investor Ups Stake in ConnectM (Nasdaq: CNTM) — Now Holds 15.1% Ownership SRISID LLC has disclosed a significant passive investment in ConnectM Technology Solutions, boosting its position to 7.55M shares — representing 15.1% of the company’s outstanding common stock. 💡 Why This Matters to Investors: 🔹 Strategic Signal: SRISID is part of the investor group behind a recent $1.60/share buy-out offer, adding weight to its long-term conviction in ConnectM's value and future potential. 🔹 Investor Confidence: The 13G filing highlights growing institutional interest in ConnectM Technology Solutions's role in the energy transition and smart infrastructure sectors. 🔹 Significant Potential Upside: The buy-out proposal suggests near-term catalysts that could unlock shareholder value. 📄 https://lnkd.in/e_VAfzSc GE Vernova GE Vernova's Electrification businesses S&P Global Commodity Insights #CNTM #AI #Electrification #EV #Investing #EnergyTransition #StockMarket

📢 Investor Alert: BullFrog AI (Nasdaq: BFRG) to Host Live Webinar – April 23, 4:15PM EST Join BullFrog AI’s investor webinar tomorrow to gain key insights into the company’s AI-powered drug discovery platform and strategic roadmap for 2024 and beyond. 💡 Why This Matters to Investors: - AI Advantage in Drug Development: Learn how bfLEAP® and BullFrog Data Networks® uncover hidden insights in complex datasets—transforming R&D for biopharma. - Tapping a $204B Opportunity: BullFrog AI addresses the low 12% success rate in Phase 1 trials with affordable, data-driven solutions. - Dual Revenue Strategy: Combining platform-driven growth with monetization of licensed drug assets and research partnerships. Don’t miss this chance to hear directly from leadership and explore what’s next for this AI-driven biotech innovator. 🔗 https://lnkd.in/eVt344HH AI News Biotechnology News Biotechnology #BullfrogAI #RedChip #RedChat #AI #BiotechStocks #BFRG #DrugDiscovery #Nasdaq #Innovation #Investing

💊 Investors: Aptevo’s (Nasdaq: APVO) December Data Still a Potential Catalyst in 2025 While the data dropped in December, Aptevo Therapeutics Inc's RAINIER results remain a key milestone—100% remission rate in Cohort 1, including a patient with TP53-mutated AML, a notoriously hard-to-treat subtype. 📊 Why It Still Resonates: • MRD-Negative Remissions suggest durability • TP53 Response highlights potential in high-risk AML • Orphan Drug Status remains a valuable regulatory asset 📄 More information available at: https://lnkd.in/ecQN_FCe Biotechnology Biotechnology News #BiotechStocks #AML #ClinicalTrials #CancerResearch #Aptevo #APVO #Oncology

Barrick (NYSE: GOLD) just sold 50% interest in Donlin, AK gold project to NOVAGOLD (NYSE American: NG) for $1B. Nova Minerals Limited (Nasdaq: NVA) already holds approx. 9.9Moz of gold at its 514 km2 project in the exact same gold belt. Learn more at: https://lnkd.in/dxKqZzJV Mines and Money S&P Global Commodity Insights Precious Metals Procurement #NovaMinerals #RedChipClient #RedChat #preciousmetals #antimony #Alaska #goldrush #Gold #MiningStocks

🦠 60 Degrees Pharmaceuticals, INC (Nasdaq: SXTP): Survey Reveals Millions May Be Living with Undiagnosed Babesiosis A new 6,000-person survey by 60 Degrees suggests that up to 3 million Americans may have contracted babesiosis—over 40x higher than CDC figures. Even more concerning: ~9.9M report chronic fatigue, a key symptom potentially linked to undiagnosed Babesia infections. 🔍 Why This Matters to Investors: - Market Underestimation: If validated, the U.S. treatment market for babesiosis may be vastly larger than previously believed. - Pipeline Opportunity: 60 Degrees is actively running two clinical trials and planning a third for its potential treatment, ARAKODA® (tafenoquine). - Strategic Positioning: With no FDA-approved drug for chronic babesiosis, 60 Degrees Pharmaceuticals, INC is aiming to fill a major treatment void in infectious disease. 🔗 https://lnkd.in/e37ZS8kq Biotechnology Biotechnology News #RedChip #RedChat #60P #SXTP #PharmaStocks #Babesiosis #BiotechInvesting #HealthcareInnovation #FinancialNews

🧬 Atossa Therapeutics (Nasdaq: ATOS): New U.S. Patent Fortifies (Z)-endoxifen IP Portfolio Atossa Therapeutics, Inc. has been granted U.S. Patent No. 12,275,684, strengthening its proprietary (Z)-endoxifen pipeline—an innovative SERM under development for hormone receptor-positive breast cancer.  💡 Why This Matters for Investors: ✅ Expanded Protection: Covers enteric oral formulations and treatment methods, enhancing IP around (Z)-endoxifen. ✅ Strategic Differentiation: Designed to preserve the active (Z)-form by bypassing stomach acid—offering a potential clinical edge over tamoxifen. ✅ Pipeline Progress: Adds to over 100 claims now protected, supporting Atossa Therapeutics, Inc.'s lead programs in breast cancer treatment and prevention. 📄 Read the Full Announcement: https://lnkd.in/eGbukmsk Breast Cancer Now Breast Cancer Trials Biotechnology News #Biotech #BreastCancer #ClinicalTrials #Oncology #Investing

🚨 OS Therapies (NYSE American: OSTX): FDA Meeting Granted to Support Accelerated Approval for OST-HER2 📢 OS Therapies has secured a written response-only FDA meeting to align on the surrogate endpoint needed to support both Breakthrough Therapy Designation and Accelerated Approval for OST-HER2, its lead immunotherapy targeting recurrent lung metastatic osteosarcoma. 🧬 Why This Matters for Investors: - Key FDA Milestone: Alignment with FDA puts OST-HER2 on track for a Q3 BLA submission and potential approval by year-end 2025. - Market Potential: OST-HER2 targets a $500M+ opportunity in preventing osteosarcoma lung metastases—an area with high unmet need and poor survival rates. - PRV Opportunity: If conditionally approved by Sept 2026, OS Therapies becomes eligible for a Priority Review Voucher, recently valued at $150M. - Upcoming Catalyst: Analysis to be showcased at the MIB Factor conference keynote on June 28, 2025. 🔗 https://lnkd.in/eGcnedPY Biotechnology Biotechnology News #RedChip #RedChat #OSTX #BiotechStocks #Immunotherapy #ADC #Investing #CancerResearch #StockMarket

📢 VENU Holding Corp. (NYSE American: VENU) Investor Webinar Today at 4:15 PM EST – Discover the Future of Live Entertainment VENU is inviting investors to a special webinar today at 4:15 PM EST. Don’t miss this deep dive into one of the most innovative models in the entertainment industry. 🎯 Why Investors Should Tune In: 💰 $77.7M in FireSuite sales for 2024, with $200M projected for 2025 🏟️ 11 new venues in development, targeting $1.5B+ in annual ticket receipts 🏆 Ford Amphitheater’s first season: 96,000 fans and $12.7M in revenue 🤝 Strategic alliances with AEG Presents, Ford Motor Company, Budweiser, The Coca-Cola Company, and NFL legend Troy Aikman VENU blends luxury real estate, public-private partnerships, and premium entertainment for scalable, high-margin growth—while maintaining a low-risk financial profile. 🔗 https://lnkd.in/d3RHCFrf VenuesNow Real Estate #RedChip #RedChat #VENU #LiveEntertainment #RevenueGrowth #Investing #SmallCapStocks #Hospitality